Setting the bar for adjuvant treatment of melanoma

摘要

There is universal agreement about the need to improve adjuvant treatment for patients who have melanoma and are at high risk of disease recurrence after surgery.12 Medical management of metastatic melanoma has improved greatly, with the approval of four new drugs that have shown clear survival benefits in phase 3 randomised trials, beginning with the approvals of ipilimumab and vemurafenib in 2011. Effective adjuvant treatment-whether with approved drugs or those in development-is important to minimise melanoma recurrence and death. The American Society of Clinical Oncology has published guidance that aims to improve the standard of clinical trials in metastatic breast, colon, lung, and pancreatic cancers by setting a higher bar for treatment expectations.